EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China

Fengyu Wen, Jinwei Wang iD, Chao Yang, Fulin Wang, Yan Li iD, Luxia Zhang

Clinical Kidney Journal · 02.11.2026 · 19 (11)

DOI: 10.1093/ckj/sfag354 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Kidney Journal, online erschienen am 09.10.2026. Verfasst von Fengyu Wen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health Data Science at Peking University, Beijing, China. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project of China, National High Level Hospital Clinical Research Funding.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fengyu Wen, Jinwei Wang, Chao Yang, Fulin Wang, Yan Li, Luxia Zhang; Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabet

Autor:innen und Institutionen

  • National Institute of Health Data Science at Peking University, Beijing, China.
  • School of Data Science and Artificial Intelligence, Beijing University of Chinese Medicine, Beijing, China.
  • Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
  • State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
  • Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Center for Digital Health and Artificial Intelligence, Peking University First Hospital, Beijing, China.

ORCID-Profile: Jinwei Wang, Yan Li

Förderung

  • National Natural Science Foundation of China
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project of China
  • National High Level Hospital Clinical Research Funding
  • State Key Laboratory of Vascular Homeostasis and Remodeling
  • Peking University
  • Young Elite Scientists Sponsorship Program by CAST
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Wen, F., Wang, J., Yang, C., Wang, F., Li, Y., & Zhang, L. (2026). Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag354

Vancouver

Wen F, Wang J, Yang C, Wang F, Li Y, Zhang L. Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag354

BibTeX
@article{Wen2026,
  author = {Wen, Fengyu and Wang, Jinwei and Yang, Chao and Wang, Fulin and Li, Yan and Zhang, Luxia},
  title = {Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China},
  journal = {Clinical Kidney Journal},
  year = {2026},
  volume = {19},
  number = {11},
  doi = {10.1093/ckj/sfag354}
}
Kostenlos starten →